BC Innovations | Aug 23, 2019
Distillery Therapeutics

KRAS inhibitor combinations for improved therapeutic efficacy

DISEASE CATEGORY: Cancer INDICATION: Lung cancer, pancreatic cancer UCSF’s Kevan Shokat and colleagues have identified two sets of genes for which inhibition could improve the efficacy of KRAS G12C inhibitors. Through a CRISPR-based screen in...
BC Innovations | Aug 21, 2019
Distillery Therapeutics

Targeting CAD or DHODH to inhibit pyrimidine synthesis for glioblastoma

DISEASE CATEGORY: Cancer INDICATION: Brain cancer Blocking pyrimidine synthesis via inhibition of CAD or DHODH, an enzyme downstream CAD, could treat glioblastoma. In patients, high tumor expression of a pyrimidine metabolism gene signature was associated...
BC Innovations | Dec 19, 2018
Distillery Therapeutics

Inflammation; pulmonary

INDICATION: Asthma; pulmonary fibrosis Mouse studies suggest an inhaled prodrug of a PI3K inhibitor could help treat asthma and pulmonary fibrosis. In mouse models of acute allergic asthma and chronic asthma, inhalation of a methylbenzoate-based...
BC Week In Review | Jul 13, 2018
Company News

Adlai Nortye gets rights to buparlisib from Novartis

Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed. Adlai Nortye has global rights to develop and commercialize...
BC Extra | Jul 10, 2018
Company News

Adlai Nortye gets rights to Novartis' buparlisib

Chinese immunotherapy company Adlai Nortye Biopharma Co. Ltd. (Hangzhou, China) gained exclusive, worldwide rights to cancer candidate buparlisib (BKM120) from Novartis AG (NYSE:NVS; SIX:NOVN). Financial terms were not disclosed. Adlai Nortye has global rights to...
BC Innovations | Mar 7, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture studies suggest inhibiting NEK9 or MAP2K4 could help treat PI3K inhibitor-resistant triple-negative breast cancer (TNBC). In tumor samples from patient-derived xenograft (PDX) mouse models of TNBC, levels of NEK9 and...
BC Innovations | Aug 16, 2017
Distillery Techniques

Disease models

TECHNOLOGY: 3-D models Self-assembling multicellular BBB spheroids could help screen compounds for BBB permeability. The spheroids self-assembled from co-cultures of primary human astrocytes, brain vascular pericytes and either brain microvascular endothelial cells or a human...
BC Innovations | Jul 10, 2017
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest inhibiting GLI1 alone or in combination with PI3K could help treat squamous cell carcinoma (SCC) of the lung. In lung tissue samples from patients,...
BC Innovations | Jun 7, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Cell culture and mouse studies suggest jointly inhibiting PI3K and either PIM2 , TACC1 , ZAK , ZFR or ZNF565 could help treat breast cancer. An shRNA screen in a human breast cancer cell line...
BioCentury | Sep 5, 2016
Strategy

Back to School: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
Items per page:
1 - 10 of 27